Alembic Pharma gets FDA approval neuropathic pain management drug

Alembic Pharma gets FDA approval for neuropathic pain management drug

7:13 AM, 22nd July 2019
Alembic Pharma logo

VADODARA, INDIA: Alembic Pharmaceuticals Limited has received approval from the US Food & Drug Administration (USFDA) for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. The approved product Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules.

Pregabalin Capsule is indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older, management offibromyalgia and management of neuropathic pain associated with spinal cord injury. Alembic had previously received tentative approval for this ANDA.

Pregabalin Capsules have an estimated market size of US$ 5.47 billion for twelve months ending December 2018 according to IQVIA. Alembic now has a total of 98 ANDA approvals (88 final approvals and 10 tentative approvals) from USFDA.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

IEA launches new tool to track methane emissions

PARIS, FRANCE: The International Energy Agency (IEA) has launched a new online tool that tracks oil & gas-related sources of methane. The new  ...

Read more
Camel dung fuels cement production in northern UAE

RAS AL-KHAIMAH, UAE: Thousands of tonnes of camel dung are being used to fuel cement production in the northern United Arab Emirates, cutting emission ...

Read more
'Bioinspired' sustainable chemistry helps cleanse our water

PITTSBURGH, US: The 20th and 21st centuries have seen an upsurge use of synthetic chemicals worldwide, including pesticides, medications and household ...

Read more
Zydus' Nesher Pharma gets FDA nod to market generic ADHD drug

NEW DELHI, INDIA: Cadila Healthcare said Zydus' Nesher Pharmaceuticals has received final nod from the US health regulator to market generic version o ...

Read more
McDermott bags pre-FEED contract for YPF’s LNG facility

HOUSTON, US: McDermott International Inc has been awarded a sizeable contract by Argentina-based YPF SA, to provide pre-front-end engineering design ( ...

Read more
Dr Reddy's launches generic version of allergy tablets in US

HYDERABAD, INDIA/ PRINCETON, US: Dr. Reddy’s Laboratories Ltd has launched Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Releas ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X